Fidelity Investments
ZYNE

Fidelity Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Fidelity Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25
Closed -$8 – 5601
2023
Q2 		$8 Sell
25
-150
-86% -$54 ﹤0.01% 5295
2023
Q1 		$75 Buy
+175
New +$92 ﹤0.01% 4932
2021
Q3 		– Sell
-1
Closed – – 5232
2021
Q2 		$0 Sell
1
-99
-99% -$476 ﹤0.01% 5075
2021
Q1 		$0 Buy
+100
New +$453 ﹤0.01% 4679
2019
Q3 		– Sell
-600
Closed -$8K – 4343
2019
Q2 		$8K Buy
+600
New +$6.93K ﹤0.01% 3292

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fidelity Investments's ZYNE Position: Q3 2023 in Review

Fidelity Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 25 shares — an estimated $8 sold.

Fidelity Investments first reported a position in ZYNE in Q2 2019 and held it in 5 quarters. The position peaked at $8K in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • Fidelity Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Fidelity Investments sold 25 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $8.
  • Fidelity Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 5 quarters.
  • Fidelity Investments's Zynerba Pharmaceuticals, Inc position peaked at $8K in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.